Literature DB >> 7507815

Isolation, identification, and biological activities of oxidative metabolites of FK506, a potent immunosuppressive macrolide lactone.

K Iwasaki1, T Shiraga, K Nagase, Z Tozuka, K Noda, S Sakuma, T Fujitsu, K Shimatani, A Sato, M Fujioka.   

Abstract

To characterize structures and biological activities of FK506 metabolites, FK506 was incubated with liver microsomes prepared from phenobarbital-treated rats in the presence of NADPH generating system under aerobic condition. Oxidative metabolites formed in the reaction medium were isolated and identified. Purified samples were analyzed by HPLC, mass spectrometry, and NMR spectroscopy. M-I, M-II, and M-III were the O-demethylated metabolites at the 13-, 31-, and 15-positions of FK506, respectively, and M-IV was the monohydroxylated metabolite at the 12-position. M-I was the dominant metabolite in this reaction system. M-II and M-III retained the tetrahydropyrane ring in their structures like FK506, but M-I and M-IV had rearranged structures in which the tetrahydropyrane ring was changed to a tetrahydrofuran ring. Measuring the immunosuppressive activity in the mouse mixed lymphocyte reaction system, IC50 values for M-I, M-II, M-III, M-IV, and FK506 were 1.65, 0.23, > 127, 5.52, and 0.15 nM, respectively. Reactivity of the metabolites with mouse anti-FK506 monoclonal antibody was studied and immunocross-reactivity of M-I, M-II, M-III, and M-IV with the antibody were nil, 109.0, 90.5, and 8.8% of FK506, respectively. These results indicate that rat hepatic microsomes oxidatively metabolize FK506 to four metabolites, and some of them exhibit pharmacological activity.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7507815

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  21 in total

1.  Identification of a new metabolite of macrolide immunosuppressant, like rapamycin and SDZ RAD, using high performance liquid chromatography and electrospray tandem mass spectrometry.

Authors:  K Hallensleben; M Raida; G Habermehl
Journal:  J Am Soc Mass Spectrom       Date:  2000-06       Impact factor: 3.109

Review 2.  PharmGKB summary: cyclosporine and tacrolimus pathways.

Authors:  Julia M Barbarino; Christine E Staatz; Raman Venkataramanan; Teri E Klein; Russ B Altman
Journal:  Pharmacogenet Genomics       Date:  2013-10       Impact factor: 2.089

Review 3.  The use of therapeutic drug monitoring to optimise immunosuppressive therapy.

Authors:  S M Tsunoda; F T Aweeka
Journal:  Clin Pharmacokinet       Date:  1996-02       Impact factor: 6.447

4.  Structural elucidation by electrospray mass spectrometry: an approach to the in vitro metabolism of the macrolide immunosuppressant SDZ RAD.

Authors:  C Vidal; G I Kirchner; K F Sewing
Journal:  J Am Soc Mass Spectrom       Date:  1998-12       Impact factor: 3.109

5.  Tacrolimus trough monitoring guided by mass spectrometry without accounting for assay differences is associated with acute kidney injury in lung transplant recipients.

Authors:  Nicholas A Kolaitis; Daniel R Calabrese; Patrick Ahearn; Aida Venado; Rebecca Florez; Huey-Ling Lei; Karolina Isaak; Erik Henricksen; Emily Martinez; Tiffany Chong; Rupal J Shah; Lorriana E Leard; Mary Ellen Kleinhenz; Jeffrey Golden; Teresa De Marco; John R Greenland; Jasleen Kukreja; Steven R Hays; Paul D Blanc; Jonathan P Singer
Journal:  Am J Health Syst Pharm       Date:  2019-12-02       Impact factor: 2.637

Review 6.  A risk-benefit assessment of tacrolimus in transplantation.

Authors:  M Winkler; U Christians
Journal:  Drug Saf       Date:  1995-05       Impact factor: 5.606

7.  Tacrolimus (FK 506) biotransformation in primary rat hepatocytes depends on extracellular matrix geometry.

Authors:  A Bader; E Knop; K H Böker; O Crome; N Frühauf; A K Gonschior; U Christians; H Esselmann; R Pichlmayr; K F Sewing
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1996-03       Impact factor: 3.000

Review 8.  Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation.

Authors:  Christine E Staatz; Susan E Tett
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

9.  Microbial Demethylation of Immunosuppressant FK-506: Isolation of 31-O-FK-506-Specific Demethylase Showing Cytochrome P-450 Characteristics from Streptomyces rimosus MA187.

Authors:  A Shafiee; T Chen; P Cameron
Journal:  Appl Environ Microbiol       Date:  1995-10       Impact factor: 4.792

10.  Protective effect of mycophenolate mofetil against nephrotoxicity and hepatotoxicity induced by tacrolimus in Wistar rats.

Authors:  Hanen Ferjani; Amira El Arem; Aicha Bouraoui; Abedellatif Achour; Salwa Abid; Hassen Bacha; Imen Boussema-Ayed
Journal:  J Physiol Biochem       Date:  2016-01-09       Impact factor: 4.158

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.